vs
艾伯维（ABBV）与RYTHM, Inc.（RYM）财务数据对比。点击上方公司名可切换其他公司
艾伯维的季度营收约是RYTHM, Inc.的1558.9倍（$16.6B vs $10.7M）。艾伯维净利率更高（10.9% vs -127.6%，领先138.6%）。RYTHM, Inc.同比增速更快（242.0% vs 10.0%）。过去两年RYTHM, Inc.的营收复合增速更高（102.6% vs 16.2%）
艾伯维是一家总部位于美国伊利诺伊州北芝加哥的制药企业，专注于研发、生产覆盖多种疾病领域的治疗药物，致力于为全球各地患者提供安全有效的临床解决方案，在全球医药行业拥有较高的知名度与影响力。
RYTHM Inc.是一家临床阶段生物制药企业，专注于研发和商业化针对罕见遗传性内分泌与代谢疾病的创新疗法，主要面向美国市场，服务存在未被满足医疗需求的儿童及成人患者群体。
ABBV vs RYM — 直观对比
营收规模更大
ABBV
是对方的1558.9倍
$10.7M
营收增速更快
RYM
高出231.9%
10.0%
净利率更高
ABBV
高出138.6%
-127.6%
两年增速更快
RYM
近两年复合增速
16.2%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $16.6B | $10.7M |
| 净利润 | $1.8B | $-13.6M |
| 毛利率 | 72.6% | 75.5% |
| 营业利润率 | 27.3% | -121.5% |
| 净利率 | 10.9% | -127.6% |
| 营收同比 | 10.0% | 242.0% |
| 净利润同比 | 8354.5% | 44.1% |
| 每股收益（稀释后） | $1.02 | $-6.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABBVRYM
| Q4 25 | $16.6B | $10.7M | ||
| Q3 25 | $15.8B | $4.0M | ||
| Q2 25 | $15.4B | $2.0M | ||
| Q1 25 | $13.3B | $538.0K | ||
| Q4 24 | $15.1B | $-7.5M | ||
| Q3 24 | $14.5B | $1.9M | ||
| Q2 24 | $14.5B | $3.0M | ||
| Q1 24 | $12.3B | $2.6M |
净利润ABBVRYM
| Q4 25 | $1.8B | $-13.6M | ||
| Q3 25 | $186.0M | $-10.7M | ||
| Q2 25 | $938.0M | $-7.4M | ||
| Q1 25 | $1.3B | $-1.6M | ||
| Q4 24 | $-22.0M | $-24.4M | ||
| Q3 24 | $1.6B | $-18.7M | ||
| Q2 24 | $1.4B | $-3.0M | ||
| Q1 24 | $1.4B | $4.2M |
毛利率ABBVRYM
| Q4 25 | 72.6% | 75.5% | ||
| Q3 25 | 66.4% | 34.0% | ||
| Q2 25 | 71.8% | 33.4% | ||
| Q1 25 | 70.0% | 16.7% | ||
| Q4 24 | 70.9% | — | ||
| Q3 24 | 70.9% | 11.6% | ||
| Q2 24 | 70.9% | 37.6% | ||
| Q1 24 | 66.7% | 6.4% |
营业利润率ABBVRYM
| Q4 25 | 27.3% | -121.5% | ||
| Q3 25 | 12.1% | -219.8% | ||
| Q2 25 | 31.7% | -332.9% | ||
| Q1 25 | 28.0% | -687.9% | ||
| Q4 24 | -9.9% | — | ||
| Q3 24 | 26.5% | -63.1% | ||
| Q2 24 | 27.6% | -28.5% | ||
| Q1 24 | 22.7% | 13.6% |
净利率ABBVRYM
| Q4 25 | 10.9% | -127.6% | ||
| Q3 25 | 1.2% | -263.8% | ||
| Q2 25 | 6.1% | -360.4% | ||
| Q1 25 | 9.6% | -302.2% | ||
| Q4 24 | -0.1% | 324.4% | ||
| Q3 24 | 10.8% | -964.4% | ||
| Q2 24 | 9.5% | -99.3% | ||
| Q1 24 | 11.1% | 163.0% |
每股收益（稀释后）ABBVRYM
| Q4 25 | $1.02 | $-6.78 | ||
| Q3 25 | $0.10 | $-5.33 | ||
| Q2 25 | $0.52 | $-3.74 | ||
| Q1 25 | $0.72 | $-0.83 | ||
| Q4 24 | $-0.03 | $-24.26 | ||
| Q3 24 | $0.88 | $-17.28 | ||
| Q2 24 | $0.77 | $-3.16 | ||
| Q1 24 | $0.77 | $3.78 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $5.3B | $32.2M |
| 总债务越低越好 | $58.9B | $80.6M |
| 股东权益账面价值 | $-3.3B | $13.0M |
| 总资产 | $134.0B | $106.7M |
| 负债/权益比越低杠杆越低 | — | 6.19× |
8季度趋势，按日历期对齐
现金及短期投资ABBVRYM
| Q4 25 | $5.3B | $32.2M | ||
| Q3 25 | $5.7B | — | ||
| Q2 25 | $6.5B | $41.0M | ||
| Q1 25 | $5.2B | $24.4M | ||
| Q4 24 | $5.6B | — | ||
| Q3 24 | $7.3B | $267.0K | ||
| Q2 24 | $13.2B | $57.0K | ||
| Q1 24 | $18.1B | $99.0K |
总债务ABBVRYM
| Q4 25 | $58.9B | $80.6M | ||
| Q3 25 | $63.0B | $90.6M | ||
| Q2 25 | $63.0B | $40.6M | ||
| Q1 25 | $64.5B | $10.6M | ||
| Q4 24 | $60.3B | — | ||
| Q3 24 | $58.5B | $6.2M | ||
| Q2 24 | $58.0B | $4.6M | ||
| Q1 24 | $63.8B | — |
股东权益ABBVRYM
| Q4 25 | $-3.3B | $13.0M | ||
| Q3 25 | $-2.6B | $11.7M | ||
| Q2 25 | $-183.0M | $21.0M | ||
| Q1 25 | $1.4B | $26.8M | ||
| Q4 24 | $3.3B | $28.1M | ||
| Q3 24 | $6.0B | $5.5M | ||
| Q2 24 | $6.8B | $8.5M | ||
| Q1 24 | $8.0B | $-5.5M |
总资产ABBVRYM
| Q4 25 | $134.0B | $106.7M | ||
| Q3 25 | $133.9B | $115.2M | ||
| Q2 25 | $137.2B | $69.5M | ||
| Q1 25 | $136.2B | $45.6M | ||
| Q4 24 | $135.2B | $54.0M | ||
| Q3 24 | $143.4B | $39.0M | ||
| Q2 24 | $141.9B | $39.4M | ||
| Q1 24 | $148.9B | $40.6M |
负债/权益比ABBVRYM
| Q4 25 | — | 6.19× | ||
| Q3 25 | — | 7.73× | ||
| Q2 25 | — | 1.94× | ||
| Q1 25 | 45.44× | 0.40× | ||
| Q4 24 | 18.15× | — | ||
| Q3 24 | 9.70× | 1.13× | ||
| Q2 24 | 8.56× | 0.54× | ||
| Q1 24 | 7.97× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $5.2B | $-3.0M |
| 自由现金流经营现金流 - 资本支出 | $4.9B | — |
| 自由现金流率自由现金流/营收 | 29.4% | — |
| 资本支出强度资本支出/营收 | 2.0% | — |
| 现金转化率经营现金流/净利润 | 2.87× | — |
| 过去12个月自由现金流最近4个季度 | $17.8B | — |
8季度趋势，按日历期对齐
经营现金流ABBVRYM
| Q4 25 | $5.2B | $-3.0M | ||
| Q3 25 | $7.0B | $-5.4M | ||
| Q2 25 | $5.2B | $-8.4M | ||
| Q1 25 | $1.6B | $-6.7M | ||
| Q4 24 | $7.0B | $-5.3M | ||
| Q3 24 | $5.4B | $-1.4M | ||
| Q2 24 | $2.3B | $-1.8M | ||
| Q1 24 | $4.0B | $-3.0M |
自由现金流ABBVRYM
| Q4 25 | $4.9B | — | ||
| Q3 25 | $6.6B | — | ||
| Q2 25 | $4.9B | — | ||
| Q1 25 | $1.4B | — | ||
| Q4 24 | $6.8B | — | ||
| Q3 24 | $5.2B | — | ||
| Q2 24 | $2.0B | $-1.8M | ||
| Q1 24 | $3.8B | $-3.0M |
自由现金流率ABBVRYM
| Q4 25 | 29.4% | — | ||
| Q3 25 | 42.1% | — | ||
| Q2 25 | 31.7% | — | ||
| Q1 25 | 10.5% | — | ||
| Q4 24 | 44.7% | — | ||
| Q3 24 | 35.9% | — | ||
| Q2 24 | 14.0% | -61.2% | ||
| Q1 24 | 31.3% | -115.1% |
资本支出强度ABBVRYM
| Q4 25 | 2.0% | — | ||
| Q3 25 | 2.4% | — | ||
| Q2 25 | 1.7% | — | ||
| Q1 25 | 1.8% | — | ||
| Q4 24 | 1.9% | — | ||
| Q3 24 | 1.7% | — | ||
| Q2 24 | 1.7% | 0.1% | ||
| Q1 24 | 1.6% | 0.1% |
现金转化率ABBVRYM
| Q4 25 | 2.87× | — | ||
| Q3 25 | 37.76× | — | ||
| Q2 25 | 5.49× | — | ||
| Q1 25 | 1.27× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.49× | — | ||
| Q2 24 | 1.66× | — | ||
| Q1 24 | 2.95× | -0.71× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ABBV
暂无分部数据
RYM
| Nonlicensing Revenue | $9.5M | 89% |
| Cultivation Business Discontinued Operations | $1.2M | 11% |
